PriceTargets.com logo

Intellia Therapeutics - NTLA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $54.94
  • Forecasted Upside: 318.41%
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$13.13 As of 12/17/2024 01:00 AM ET
▼ -0.25 (-1.87%)

This chart shows the closing price for NTLA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intellia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTLA

Analyst Price Target is $54.94
▲ +318.41% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $54.94, with a high forecast of $120.00 and a low forecast of $14.00. The average price target represents a 318.41% upside from the last price of $13.13.

This chart shows the closing price for NTLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 18 investment analysts is to moderate buy stock in Intellia Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
11/18/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$80.00 ➝ $70.00
11/18/2024WedbushReiterated RatingNeutral ➝ Neutral$14.00 ➝ $14.00
11/18/2024William BlairReiterated RatingNeutral$14.00
11/18/2024Chardan CapitalBoost TargetBuy ➝ Buy$88.00 ➝ $91.00
11/11/2024OppenheimerLower TargetOutperform ➝ Outperform$70.00 ➝ $60.00
11/8/2024BarclaysLower TargetOverweight ➝ Overweight$76.00 ➝ $55.00
11/7/2024WedbushReiterated RatingNeutral$14.00
10/25/2024CitigroupLower TargetNeutral ➝ Neutral$25.00 ➝ $19.00
10/25/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$31.00 ➝ $20.00
10/25/2024Robert W. BairdLower TargetNeutral ➝ Neutral$24.00 ➝ $18.00
10/24/2024Chardan CapitalLower TargetBuy ➝ Buy$94.00 ➝ $88.00
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$54.00 ➝ $54.00
9/11/2024Stifel NicolausLower TargetBuy ➝ Buy$80.00 ➝ $64.00
8/12/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$61.00 ➝ $55.00
8/9/2024Evercore ISIUpgradeStrong-Buy
8/9/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$60.00 ➝ $54.00
6/27/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
6/24/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
6/24/2024Truist FinancialReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
6/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
6/4/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
5/10/2024CitigroupLower TargetNeutral ➝ Neutral$31.00 ➝ $29.00
5/10/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$62.00 ➝ $70.00
4/23/2024WedbushReiterated RatingNeutral ➝ Neutral$29.00
2/23/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$72.00 ➝ $73.00
2/23/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral$136.00 ➝ $32.00
2/15/2024WedbushReiterated RatingNeutral$29.00
2/15/2024Wolfe ResearchInitiated CoveragePeer Perform
11/13/2023OppenheimerLower TargetOutperform ➝ Outperform$80.00 ➝ $70.00
11/13/2023Morgan StanleyLower TargetOverweight ➝ Overweight$90.00 ➝ $85.00
11/10/2023Raymond JamesLower TargetOutperform ➝ Outperform$78.00 ➝ $57.00
11/10/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$157.00 ➝ $136.00
11/10/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$80.00 ➝ $70.00
11/10/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$64.00 ➝ $62.00
11/2/2023WedbushReiterated RatingNeutral$45.00
10/18/2023WedbushReiterated RatingNeutral$48.00 ➝ $45.00
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
8/29/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
8/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
8/7/2023Chardan CapitalReiterated RatingBuy ➝ Buy$107.00
8/7/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$66.00 ➝ $65.00
8/4/2023BarclaysLower TargetOverweight ➝ Overweight$148.00 ➝ $90.00
8/4/2023CitigroupLower TargetNeutral ➝ Neutral$44.00 ➝ $40.00
6/13/2023Bank of AmericaBoost Target$89.00 ➝ $91.00
6/13/2023Chardan CapitalLower Target$111.00 ➝ $107.00
5/5/2023BMO Capital MarketsBoost Target$57.00 ➝ $64.00
4/13/2023Canaccord Genuity GroupInitiated CoverageBuy$66.00
3/31/2023JPMorgan Chase & Co.Lower TargetOverweight$82.00 ➝ $79.00
3/22/2023William BlairReiterated RatingOutperform
3/21/2023Sanford C. BernsteinInitiated CoverageOutperform$54.00
3/13/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$54.00 ➝ $57.00
2/24/2023Chardan CapitalLower TargetBuy$129.00 ➝ $111.00
2/24/2023Raymond JamesLower TargetOutperform$124.00 ➝ $94.00
2/24/2023EF Hutton Acquisition Co. ILower TargetBuy$123.00 ➝ $116.00
2/24/2023OppenheimerLower TargetOutperform$115.00 ➝ $93.00
2/24/2023Credit Suisse GroupLower TargetOutperform$88.00 ➝ $76.00
2/24/2023Robert W. BairdLower TargetNeutral$58.00 ➝ $42.00
1/31/2023Cantor FitzgeraldInitiated CoverageOverweight$67.00
1/24/2023CitigroupUpgradeSell ➝ Neutral$48.00 ➝ $39.00
1/23/2023Leerink PartnersLower TargetOutperform$86.00 ➝ $84.00
1/19/2023JMP SecuritiesDowngradeOutperform ➝ Market Perform
1/4/2023Wells Fargo & CompanyLower TargetOverweight$135.00 ➝ $120.00
12/6/2022Credit Suisse GroupLower TargetOutperform$109.00 ➝ $88.00
12/2/2022Leerink PartnersLower TargetOutperform$90.00 ➝ $86.00
11/14/2022Chardan CapitalBoost TargetBuy$121.00 ➝ $129.00
11/4/2022Morgan StanleyLower TargetOverweight$84.00 ➝ $83.00
11/4/2022Raymond JamesLower TargetOutperform$127.00 ➝ $124.00
11/4/2022Credit Suisse GroupBoost TargetOutperform$101.00 ➝ $109.00
11/3/2022Chardan CapitalLower TargetBuy$146.00 ➝ $121.00
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$130.00
10/11/2022Morgan StanleyInitiated CoverageOverweight$84.00
9/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$85.00
9/19/2022Leerink PartnersBoost TargetOutperform$152.00 ➝ $158.00
9/19/2022JMP SecuritiesBoost TargetMarket Outperform$106.00 ➝ $111.00
9/16/2022Chardan CapitalReiterated RatingBuy$146.00
9/1/2022CitigroupInitiated CoverageSell$50.00
8/9/2022Credit Suisse GroupBoost Target$101.00
8/5/2022Leerink PartnersLower TargetOutperform$155.00 ➝ $152.00
8/5/2022Chardan CapitalLower TargetBuy$172.00 ➝ $146.00
6/16/2022BMO Capital MarketsInitiated CoverageMarket Perform$54.00
6/16/2022Bank of AmericaInitiated CoverageBuy$70.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$206.00 ➝ $180.00
5/9/2022OppenheimerLower Target$160.00 ➝ $130.00
5/9/2022JMP SecuritiesLower Target$165.00 ➝ $110.00
4/28/2022Credit Suisse GroupInitiated CoverageOutperform$100.00
3/21/2022JMP SecuritiesReiterated RatingBuy$165.00
3/7/2022Brookline Capital AcquisitionUpgradeHold ➝ Buy$91.00
3/7/2022Brookline Capital ManagementUpgradeHold ➝ Buy$91.00
3/1/2022Chardan CapitalLower TargetBuy$177.00 ➝ $172.00
3/1/2022Robert W. BairdLower Target$146.00 ➝ $83.00
2/18/2022William BlairInitiated CoverageOutperform$144.00
2/14/2022Brookline Capital AcquisitionInitiated CoverageHold
2/14/2022Brookline Capital ManagementReiterated RatingBuy
2/7/2022OppenheimerUpgradeMarket Perform ➝ Outperform$145.00 ➝ $150.00
1/31/2022CowenInitiated CoverageOutperform
1/7/2022JMP SecuritiesLower TargetMarket Outperform$175.00 ➝ $165.00
1/7/2022Piper SandlerInitiated CoverageOverweight$171.00
11/5/2021OppenheimerLower TargetMarket Perform$160.00 ➝ $145.00
11/5/2021HC WainwrightBoost TargetBuy$171.00 ➝ $182.00
10/21/2021HC WainwrightReiterated RatingBuy$172.00
10/5/2021GuggenheimInitiated CoverageBuy$170.00
9/23/2021Stifel NicolausInitiated CoverageBuy$173.00
9/16/2021Chardan CapitalReiterated RatingBuy$177.00
9/13/2021HC WainwrightReiterated RatingBuy$171.00
8/6/2021JMP SecuritiesBoost TargetMarket Outperform$160.00 ➝ $175.00
8/6/2021The Goldman Sachs GroupBoost TargetBuy$225.00 ➝ $252.00
8/6/2021OppenheimerBoost TargetMarket Perform$125.00 ➝ $160.00
8/6/2021Chardan CapitalBoost TargetBuy$130.00 ➝ $177.00
8/6/2021Raymond JamesBoost TargetOutperform$168.00 ➝ $181.00
8/5/2021Roth CapitalBoost TargetBuy$110.00 ➝ $180.00
7/7/2021Chardan CapitalReiterated RatingBuy
7/1/2021Robert W. BairdReiterated RatingHold$85.00
6/29/2021OppenheimerBoost TargetMarket Perform$73.00 ➝ $125.00
6/29/2021Raymond JamesBoost TargetOutperform$106.00 ➝ $168.00
6/28/2021Royal Bank of CanadaBoost TargetOutperform$110.00 ➝ $150.00
6/28/2021Truist FinancialBoost TargetBuy$80.00 ➝ $160.00
6/28/2021WedbushBoost TargetNeutral$73.00 ➝ $87.00
6/28/2021Roth CapitalBoost TargetBuy$80.00 ➝ $110.00
6/28/2021The Goldman Sachs GroupBoost TargetBuy$115.00 ➝ $163.00
6/28/2021BarclaysBoost TargetPositive ➝ Overweight$88.00 ➝ $134.00
6/28/2021HC WainwrightBoost TargetBuy$111.00 ➝ $171.00
6/26/2021Chardan CapitalBoost TargetBuy$85.00 ➝ $130.00
6/23/2021Robert W. BairdBoost TargetPositive ➝ Neutral$60.00 ➝ $85.00
6/23/2021JMP SecuritiesBoost TargetPositive ➝ Outperform$80.00 ➝ $88.00
6/22/2021Jefferies Financial GroupBoost TargetBuy$83.00 ➝ $109.00
6/22/2021HC WainwrightReiterated RatingBuy$111.00 ➝ $171.00
6/11/2021HC WainwrightInitiated CoverageBuy$111.00
6/9/2021Raymond JamesReiterated RatingBuy
5/7/2021Roth CapitalUpgradeNeutral ➝ Buy$75.00 ➝ $80.00
5/3/2021Royal Bank of CanadaInitiated CoverageOutperform$110.00
3/21/2021Leerink PartnersReiterated RatingBuy
3/4/2021JMP SecuritiesInitiated CoverageOutperform$80.00
2/26/2021Truist FinancialBoost Target$40.00 ➝ $80.00
2/10/2021Chardan CapitalBoost TargetBuy$57.50 ➝ $85.00
1/8/2021Raymond JamesBoost TargetOutperform$39.00 ➝ $106.00
1/8/2021BarclaysBoost TargetOverweight$46.00 ➝ $90.00
12/22/2020Robert W. BairdDowngradeOutperform ➝ Neutral$60.00
12/21/2020Leerink PartnersBoost TargetOutperform$27.00 ➝ $61.00
12/7/2020Wells Fargo & CompanyBoost TargetOverweight$38.00 ➝ $52.00
11/5/2020Leerink PartnersReiterated RatingOutperform
10/27/2020Truist FinancialInitiated CoverageBuy$40.00 ➝ $40.00
10/27/2020Summer StreetInitiated CoverageBuy
10/19/2020Roth CapitalBoost TargetReduce ➝ Neutral$16.00 ➝ $26.00
10/14/2020Wells Fargo & CompanyInitiated CoverageOverweight
9/30/2020OppenheimerReiterated RatingHold
9/18/2020The Goldman Sachs GroupInitiated CoverageBuy$33.00
8/6/2020Chardan CapitalReiterated RatingBuy
6/2/2020Credit Suisse GroupBoost TargetNeutral$19.00 ➝ $21.00
6/1/2020WedbushBoost TargetNeutral$16.00 ➝ $20.00
6/1/2020Chardan CapitalReiterated RatingBuy$57.50
5/8/2020OppenheimerReiterated RatingHold
4/2/2020BTIG ResearchReiterated RatingBuy$22.00
3/31/2020Chardan CapitalReiterated RatingBuy$57.50
2/28/2020OppenheimerUpgradeMarket Perform ➝ Outperform
2/14/2020WedbushDowngradeOutperform ➝ Neutral$21.00 ➝ $16.00
2/10/2020Chardan CapitalReiterated RatingBuy$57.50
1/9/2020Chardan CapitalReiterated RatingBuy$57.50
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 16 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 7 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 17 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/19/2024
  • 20 very positive mentions
  • 30 positive mentions
  • 10 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 19 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 19 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Intellia Therapeutics logo
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $13.13
Low: $12.90
High: $13.51

50 Day Range

MA: $15.95
Low: $12.90
High: $21.08

52 Week Range

Now: $13.13
Low: $12.47
High: $34.87

Volume

2,913,169 shs

Average Volume

1,766,810 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Intellia Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Intellia Therapeutics in the last year: Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., Wedbush, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for NTLA.

What is the current price target for Intellia Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Intellia Therapeutics in the last year. Their average twelve-month price target is $54.94, suggesting a possible upside of 318.4%. Truist Financial Co. has the highest price target set, predicting NTLA will reach $120.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $14.00 for Intellia Therapeutics in the next year.
View the latest price targets for NTLA.

What is the current consensus analyst rating for Intellia Therapeutics?

Intellia Therapeutics currently has 6 hold ratings, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NTLA.

What other companies compete with Intellia Therapeutics?

Other companies that are similar to Intellia Therapeutics include Viking Therapeutics, TG Therapeutics, BridgeBio Pharma, Crinetics Pharmaceuticals and Krystal Biotech. Learn More about companies similar to Intellia Therapeutics.

How do I contact Intellia Therapeutics' investor relations team?

Intellia Therapeutics' physical mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company's listed phone number is (857) 285-6200 and its investor relations email address is [email protected]. The official website for Intellia Therapeutics is www.intelliatx.com. Learn More about contacing Intellia Therapeutics investor relations.